Jennifer Hsiao, MD
Dermatology · Los Angeles, CANPI 1548559131
Payments from drug & device makers
Across 1,055 payments — averaging $1085.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$368K
- UCB, Inc.$213K
- Sanofi$179K
- Novartis$135K
- AbbVie$91K
- Boehringer Ingelheim$44K
- plus $116K from 18 others
Across 10 payments — averaging $2765.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$25K
- UCB, Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 486 | $368,245 |
| UCB, Inc. | 180 | $213,024 |
| Sanofi | 66 | $178,541 |
| Novartis | 121 | $134,615 |
| AbbVie | 81 | $90,805 |
| Boehringer Ingelheim | 17 | $44,298 |
| Regeneron Healthcare Solutions, Inc. | 31 | $42,301 |
| Amgen | 5 | $32,233 |
| Galderma Laboratories, L.p. | 28 | $21,888 |
| UCB SA | 6 | $14,303 |
| LEO Pharma Inc. | 5 | $2,084 |
| Boehringer Ingelheim International GmbH | 4 | $1,261 |
| Dermavant Sciences, Inc. | 8 | $761 |
| E.r. Squibb & Sons, L.L.C. | 2 | $208 |
| Sun Pharmaceutical Industries Inc. | 1 | $137 |
| Avita Medical Americas, LLC | 3 | $129 |
| Organogenesis Inc. | 1 | $125 |
| Lilly USA, LLC | 3 | $83 |
| Arcutis Biotherapeutics, Inc. | 2 | $80 |
| Cipher Pharmaceuticals US LLC | 1 | $68 |
| Janssen Research & Development, LLC | 1 | $64 |
| Janssen Scientific Affairs, LLC | 1 | $33 |
| Organon | 1 | $29 |
| DUSA Pharmaceuticals, Inc. | 1 | $23 |
How this compares
$1,145,337 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in Los Angeles
- Howard SofenLos Angeles$16.1M
- April ArmstrongLos Angeles$6.2M
- Christopher HoLos Angeles$2M
- Pearl GrimesLos Angeles$1.6M
- Jonathan CotliarLos Angeles$1.4M
- Derek JonesLos Angeles$1.1M
- Roger LoLos Angeles$727K
- Vivian LaquerIrvine$20.9M
- Raja SivamaniSacramento$11.8M
- Jennifer SoungSanta Ana$10.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.